Neurocrine Biosciences (NBIX) Tops Q4 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $146.10 -0.19%
EPS Growth %: -12.0%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -12.0%
Financial Fact:
Deferred gain on real estate: 853K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q4 EPS of $1.54, $0.33 better than the analyst estimate of $1.21. Revenue for the quarter came in at $515.2 million versus the consensus estimate of $518.2 million.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Neurocrine Biosciences Launches Interactive Educational Resources to Support Clinical Learning in Classic Congenital Adrenal Hyperplasia
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
